Prognostic factors in breast cancer: A brief review

Anticancer Research

Volumn 18, Issue 3 C, 1998, Pages 2167-2171

  Fernö, Mårten ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; Prognosis; Treatment prediction

Indexed keywords

CELL MARKER; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MULTIVARIATE ANALYSIS; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0031928851     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Early Breast Cancer Trialist's Collaborative Group: Systematic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339: 1-15 and 71-85, 1992.
2. Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S and Bastert G: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer 88: 1652-1664, 1996.
3. Luppi M, Morselli M, Banderi E, Federico M, Marasca R, Barozzi P, Ferrari MG, Savarinon M, Frassoldati A and Torelli G: Sensitive detection of circulating breast cancer cells by reverse-transcriptase polymerase chain reaction of maspin gene. Annals Oncol 7: 619-624, 1996.
4. Baldursson G: Prognostic significance of lymph node status in stage III breast cancer. Acta Oncol 27: 317-321, 1988.
5. Galea MH, Blamey RW, Elston CE and Ellis IO: The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 22: 207-219, 1992.
6. Bloom HJG and Richardson WW: Histologic grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377, 1957.
7. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
8. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 20: 479-489, 1992.
9. Balslev I, Axelsson CK, Zedeler K, Bruun Rasmussen B, Carstensen B, and Mouridsen H: The Nottingham prognostic index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat 32: 281-290, 1994.
10. Sauerbrei W, Hübner K, Schmoor C and Schumacher M for the German Breast Cancer Study Group: Validation of existing and development of new prognostic classification schemes in node negative breast cancer. Breast Cancer Res Treat 42: 149-163, 1997.
11. Gilchrist KW, Kalish L, Gould VE, Hirschl S, Imbriglia JE, Levy WM, Patchefsky AS, Penner DW, Pickren J, Roth JA, Schinella RA, Schwartz IS and Wheeler JE: Interobserver reproducibility of histopathological features in stage II breast cancer. Breast Cancer Res Treat 5: 3-10, 1985.
12. Dalton LW, Page DL and Dupont WD: Histologic grading of breast carcinoma. A reproducibility study. Cancer 73: 2765-2770, 1994.
13. Frierson HF. Wolber RA, Berean KW, Franquemont DW, Gaffey MJ, Boyd JC and Wilbur DC: Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 103: 195-198, 1995.
14. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, Ellis I and Elston C: Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 26: 873-879, 1995.
15. Folca PJ, Glascock RF and Irvine WT: Studies with tritium-labelled hexoestrol in advanced breast cancer. Lancet ii: 796-798, 1961.
16. Jensen EV, Polley TZ, Smith S, Block GE, Ferguson DJ and DeSombre ER: Prediction of hormone dependency in human breast cancer. In: Estrogen receptors in human breast cancer (McGuire WL, Carbone PP and Vollmer EP, eds) New York, Raven Press, 1975, pp 37-55.
17. McGuire WL: Steroid receptors in human breast cancer. Cancer Res 38: 4289-4291, 1978.
18. Predine J, Spyratos F, Prud'homme JF, Andrieu C, Hacene K, Brunet M, Pallud C and Milgrom E: Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Cancer 69: 2116-2123, 1992.
19. Borg Å, Baldetorp B, Fernö M, Killander D, Olsson H, Rydén S and Sigurdsson H: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer letters 81: 137-144, 1994.
20. Butta A, Maclennon K, Flanders KC, Sacks NPM, Smith I, Mackinna A, Dowsett M, Wakefield LM, Sporn MB, Baum M and Colletta AA: Induction of transforming growth factor betal in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52: 4261-4264, 1992.
21. Silvestrini R, Daidone MG and Gasparini G: Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 56: 1982-1987, 1985.
22. Meyer JS, Friedman E, McCrate MM and Bauer W: Prediction of early course of breast carcinoma by thymidine labeling. Cancer 51: 1879-1886, 1983.
23. Baak JPA, van Dop H, Kurver PHJ, and Herman J: The value of morphometry to classic prognosticators in breast cancer. Cancer 56: 372-382, 1985.
24. Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T and McGuire WL: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627-633, 1989.
25. Sigurdsson H, Baldetorp B, Borg Å, Dalberg M, Fernö M, Killander D and Olsson H: Indicators of prognosis in node-negative breast cancer. N Engl J Med 322: 1045-1053, 1990.
26. Railo M, Nordling S, von Boguslawsky K, Leivonen M, Kyllonen L and von Smitten K: Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 68: 579-583, 1993.
27. Romain S, Christensen IJ, Chinot O, Balslev I, Rose C, Martin P-M and Thorpe SM: Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer. Int J Cancer 61: 7-12, 1995.
28. Remvikos Y, Beuzeboc P, Zajdela, Voillemot N, Magdalιnat and Pouillart P: Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 81: 1383-1387, 1989.
29. Stål O, Skoog L, Rutqvist LE, Carstensen JM, Wingren S, Sullivan S, Andersson C, Dufmats M and Nordenskjöld B: S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. Br J Cancer 70: 1258-1262, 1994.
30. Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T and Merkel D: Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 14: 482-485, 1993.
31. Auer GU, Caspersson TO, Wallgren AS: DNA content and survival in mammary carcinoma. Analyt Quant Cytol 2: 161-165, 1980.
32. Baldetorp B, Fernö M, Fallenius A, Fallenius-Vecchi G, Idvall I, Olsson H, Sigurdsson H, Åkerman M and Killander D: Image cytometric DNA analysis in human breast cancer analysis may add prognostic information in diploid cases with low S-phase fraction by flow cytometry. Cytometry 13: 577-585, 1992.
33. Fernö M, Baldetorp B, Ewers S-B, Idvall I, Olsson H, Sigurdsson H and Killander D: One or multiple samplings for flow cytometric DNA analyses in breast cancer - prognostic implications? Cytometry 13: 241-249, 1992.
34. Baldetorp B, Bendahl P-O, Fernö M, Alanen K, Delle U, Falkmer U, Hansson-Aggesjö B, Höckenström T, Lindgren A, Mossberg L, Nordling S, Sigurdsson H, Stål O and Visakorpi T: Reproducibility in DNA flow cytometry analysis of breast cancer: comparison of 12 laboratories' results for 67 sample homogenates. Cytometry (Comm Clin Cytometry) 22: 115-127, 1995.
35. Westley B and Rochefort H: A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 20: 353-362, 1980.
36. Rochefort H, Capony F, Garcia M, Cavallιs V, Freiss G, Chambon M, Morisset M and Vignon F: Estrogen-induced lysosomal proteases secreted by human breast cancer cells: a role in carcinogenesis? J Cell Biochem 35: 17-29, 1987.
37. Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, Paolucci F, Pau B, Bruun Rasmussen B and Rose C: Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49: 6008-6014, 1989.
38. Spyratos F, Maudelonde T, Brouillet J-P, Brunet M, Defrenne A, Andrieu C, Hacene K, Desplaces A, Rouxsse J and Rochefort H: Cathepsin D. an independent prognostic factor for metastasis of breast cancer. Lancet ii: 1115-1118, 1989
39. Tandon A, Clark GM, Chamness GC, Chirgwin J and McGuire WL: Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297-302, 1990.
40. Ravdin PM. Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treat 24: 219-226, 1993.
41. Thomssen C, Smith M, Goretzki L, Oppelt P, Pache L, Dettmar P, Janicke F and Graeff H: Prognostic value of cysteine proteases cathepsin B and cathepsin L in human breast cancer. Clin Cancer Res 1: 741-746, 1995.
42. Åstedt B and Holmberg L: Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature: 261, 1976.
43. Duffy MJ: Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618, 1996.
44. Foekens JA, Buessecker F, Peters HA, Krainick U, van Putten WLJ, Look MP, Klijn JGM and Kramer MD: Plasminogen activator inhibitor-2. prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 55: 1423-1427, 1995.
45. Engel G, Heselmeyer K, Auer G, Backdahl, Eriksson E and Linder S: Correlation between stromelysin-3 mRNA level and outcome of human breast cancer. Int J Cancer 58: 830-835, 1994.
46. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H and Tominaga T: Prognostic significance of vascular endothelial growth factor protein in node-negative breast cancer. J Natl Cancer Inst 89: 139-147, 1997.
47. Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR and Hellman S: Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 88: 1764-1769, 1996.
48. Folkman J: The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res Treat 36: 109-118, 1995.
49. Stål O, Sullivan S, Wingren S, Skoog L, Rutqvist LE, Carstensen JM and Nordenskjöld B: c-erbB2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31A: 2185-2190, 1995.
50. Jansson T, Inganäs M, Sjögren S, Norberg T, Lindgren A, Holmberg L and Bergh J: p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 13: 2745-2751, 1995.
51. Binder C, Marx D, Overhoff R, Binder L, Schauer A and Hiddemann W: Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Annals Oncol 6: 1005-1010, 1995.
52. Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P and Van Marck E: Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72: 354-360, 1995.